JP5329538B2 - 粘膜炎の治療において有用な方法および組成物 - Google Patents

粘膜炎の治療において有用な方法および組成物 Download PDF

Info

Publication number
JP5329538B2
JP5329538B2 JP2010516038A JP2010516038A JP5329538B2 JP 5329538 B2 JP5329538 B2 JP 5329538B2 JP 2010516038 A JP2010516038 A JP 2010516038A JP 2010516038 A JP2010516038 A JP 2010516038A JP 5329538 B2 JP5329538 B2 JP 5329538B2
Authority
JP
Japan
Prior art keywords
mucositis
sap
cancer
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010516038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532787A5 (enExample
JP2010532787A (ja
Inventor
デイビッド ポール ヘッソン，
マイケル スコット クレーマー，
Original Assignee
プロメディオール， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/215,700 external-priority patent/US9884899B2/en
Application filed by プロメディオール， インコーポレイテッド filed Critical プロメディオール， インコーポレイテッド
Publication of JP2010532787A publication Critical patent/JP2010532787A/ja
Publication of JP2010532787A5 publication Critical patent/JP2010532787A5/ja
Application granted granted Critical
Publication of JP5329538B2 publication Critical patent/JP5329538B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
JP2010516038A 2007-07-06 2008-07-07 粘膜炎の治療において有用な方法および組成物 Expired - Fee Related JP5329538B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95863407P 2007-07-06 2007-07-06
US60/958,634 2007-07-06
US96134307P 2007-07-20 2007-07-20
US60/961,343 2007-07-20
US12/215,700 2008-06-27
US12/215,700 US9884899B2 (en) 2007-07-06 2008-06-27 Methods for treating fibrosis using CRP antagonists
PCT/US2008/008340 WO2009009034A2 (en) 2007-07-06 2008-07-07 Methods and compositions useful in the treatment of mucositis

Publications (3)

Publication Number Publication Date
JP2010532787A JP2010532787A (ja) 2010-10-14
JP2010532787A5 JP2010532787A5 (enExample) 2012-08-16
JP5329538B2 true JP5329538B2 (ja) 2013-10-30

Family

ID=40076757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010516038A Expired - Fee Related JP5329538B2 (ja) 2007-07-06 2008-07-07 粘膜炎の治療において有用な方法および組成物

Country Status (9)

Country Link
EP (1) EP2185581B1 (enExample)
JP (1) JP5329538B2 (enExample)
CA (1) CA2692682C (enExample)
DK (1) DK2185581T3 (enExample)
ES (1) ES2554167T3 (enExample)
HU (1) HUE026850T2 (enExample)
PL (1) PL2185581T3 (enExample)
PT (1) PT2185581E (enExample)
WO (1) WO2009009034A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5220025B2 (ja) 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
PT2405929T (pt) 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
EP3669885A1 (en) * 2018-12-20 2020-06-24 Humanitas Mirasole S.p.A. Use of sap for the treatment of eurotiomycetes fungi infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021364A1 (en) * 1991-05-31 1992-12-10 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
WO1999005394A1 (en) * 1997-07-23 1999-02-04 Cleansorb Limited Methods for deposition of materials in underground reservoirs
AU2006290437A1 (en) * 2005-05-13 2007-03-22 Eisai R&D Management Co., Ltd. Methods of reducing the severity of oral and gastrointestinal mucositis
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
JP5220025B2 (ja) * 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法

Also Published As

Publication number Publication date
HUE026850T2 (en) 2016-08-29
WO2009009034A3 (en) 2009-02-26
EP2185581B1 (en) 2015-09-02
DK2185581T3 (en) 2015-12-14
EP2185581A2 (en) 2010-05-19
PT2185581E (pt) 2015-12-09
WO2009009034A2 (en) 2009-01-15
AU2008275693A1 (en) 2009-01-15
ES2554167T3 (es) 2015-12-16
CA2692682C (en) 2017-05-02
CA2692682A1 (en) 2009-01-15
JP2010532787A (ja) 2010-10-14
PL2185581T3 (pl) 2016-01-29

Similar Documents

Publication Publication Date Title
CA2692682C (en) Sap polypeptides useful in the treatment of mucositis
Wang et al. HMGB1 as a late mediator of lethal systemic inflammation
US8497243B2 (en) Methods and compositions useful in the treatment of mucositis
US11571427B2 (en) Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
US20090022704A1 (en) Method for the treatment of gout or pseudogout
CN102448484A (zh) 调节角质化细胞增生和分化的方法
US11993640B2 (en) Treating inflammatory lung disease
TW202039555A (zh) ＩＬ-１β結合抗體之用途
WO2023001304A1 (zh) 预防、缓解或治疗黏膜黏连的药物及其应用
JP2018065814A (ja) Ｈｅｒｖ−ｗエンベロープタンパク質発現関連疾患において再ミエリン化遮断を治療するための化合物
CN114007633A (zh) 作为治疗前列腺癌的新型标志物的ephb4-肝配蛋白b2受体配体对
Quinn et al. Effects of dantrolene therapy on disease phenotype in dystrophin deficient mdx mice
Adhyatmika et al. Osteoprotegerin expression in liver is induced by IL13 through TGFβ
CA2709224C (en) Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
Takemoto et al. An herbal medicine, Go-sha-jinki-gan (GJG), increases muscle weight in severe muscle dystrophy model mice
AU2008275693B2 (en) Methods and compositions useful in the treatment of mucositis
Cerqueira et al. BET protein inhibition promotes non-myeloid cell mediated neuroprotection after rodent spinal cord contusion
RU2741228C2 (ru) Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
CN114980901A (zh) 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法
CN115279393A (zh) 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭
CN111588854A (zh) Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用
HK40038930A (en) Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment
EA023383B1 (ru) Способ подавления роста опухоли и лечения заболеваний путем избирательного ингибирования участков рецепторов с тирозинкиназной активностью

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120625

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120907

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130724

R150 Certificate of patent or registration of utility model

Ref document number: 5329538

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees